CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy

Hadiloo, Kaveh; Tahmasebi, Safa; Esmaeilzadeh, Abdolreza

doi:10.1186/s12935-023-02923-9

Cited by 20 publications

(7 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that other immune cells such as CAR-NKT and CAR-neutrophils may also be useful for immunotherapy of solid tumors. According to preliminary data, their use has yielded tangible results in in vitro and in vivo studies [ 256 , 257 ].…”

Section: The Cancer Immunotherapy Strategiesmentioning

confidence: 99%

Contemporary Approaches to Immunotherapy of Solid Tumors

Kuznetsova,

Glukhova,

Popova

et al. 2024

Cancers

View full text Add to dashboard Cite

In recent years, the arrival of the immunotherapy industry has introduced the possibility of providing transformative, durable, and potentially curative outcomes for various forms of malignancies. However, further research has shown that there are a number of issues that significantly reduce the effectiveness of immunotherapy, especially in solid tumors. First of all, these problems are related to the protective mechanisms of the tumor and its microenvironment. Currently, major efforts are focused on overcoming protective mechanisms by using different adoptive cell therapy variants and modifications of genetically engineered constructs. In addition, a complex workforce is required to develop and implement these treatments. To overcome these significant challenges, innovative strategies and approaches are necessary to engineer more powerful variations of immunotherapy with improved antitumor activity and decreased toxicity. In this review, we discuss recent innovations in immunotherapy aimed at improving clinical efficacy in solid tumors, as well as strategies to overcome the limitations of various immunotherapies.

show abstract

Section: The Cancer Immunotherapy Strategiesmentioning

confidence: 99%

Contemporary Approaches to Immunotherapy of Solid Tumors

Kuznetsova,

Glukhova,

Popova

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Building upon this momentum, chimeric antigen receptor natural killer (CAR-NK) and chimeric antigen receptor natural killer T (CAR-NKT) cells are being recognized as formidable additions to the ACT spectrum [ 115 , 116 , 117 ]. Their inherent capabilities for immediate tumor recognition and destruction, coupled with a lower likelihood of adverse effects, mark them as promising contenders for future ccRCC therapies [ 118 , 119 ].…”

Section: Other Immune-based Therapiesmentioning

confidence: 99%

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma

Meng,

Collier,

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). While localized ccRCC can be cured with surgery, metastatic disease has a poor prognosis. Recently, immunotherapy has emerged as a promising approach for advanced ccRCC. This review provides a comprehensive overview of the evolving immunotherapeutic landscape for metastatic ccRCC. Immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 and CTLA-4 inhibitors have demonstrated clinical efficacy as monotherapies and in combination regimens. Combination immunotherapies pairing ICIs with antiangiogenic agents, other immunomodulators, or novel therapeutic platforms such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy are areas of active research. Beyond the checkpoint blockade, additional modalities including therapeutic vaccines, cytokines, and oncolytic viruses are also being explored for ccRCC. This review discusses the mechanisms, major clinical trials, challenges, and future directions for these emerging immunotherapies. While current strategies have shown promise in improving patient outcomes, continued research is critical for expanding and optimizing immunotherapy approaches for advanced ccRCC. Realizing the full potential of immunotherapy will require elucidating mechanisms of response and resistance, developing predictive biomarkers, and rationally designing combination therapeutic regimens tailored to individual patients. Advances in immunotherapy carry immense promise for transforming the management of metastatic ccRCC.

show abstract

“…In this scenario, immunotherapy has emerged as a promising approach, leveraging the body's immune system to target cancer cells [8]. However, its efficacy in treating solid tumors has been limited due to their inherent complexity [9].…”

Section: Introductionmentioning

confidence: 99%

“…Despite the availability of over 200 approved anti-cancer drugs, none have proven effective in inhibiting or treating cancer metastasis [7], underscoring the urgent need for innovative therapeutic regimens. In this scenario, immunotherapy has emerged as a promising approach, leveraging the body’s immune system to target cancer cells [8]. However, its efficacy in treating solid tumors has been limited due to their inherent complexity [9].…”

Section: Introductionmentioning

confidence: 99%

The molecular basis of the anticancer effect of statins

Buccioli,

Testa,

Jacchetti

et al. 2024

Preprint

View full text Add to dashboard Cite

Statins, one of the most used class of cardiovascular drugs with the primary function of reducing blood cholesterol levels, exert their effect by inhibiting the enzyme HMG-CoA reductase, the key player in cholesterol biosynthesis. While the primary indication for statins is the prevention of cardiovascular diseases, there has been growing interest in their potential anticancer effects. However, the current evidence on these effects is largely based on epidemiological observations and preclinical research, not yet substantiated by knowledge of the mechanisms behind it. Here we show that statins have an anticancer effect as they exploit the principle of Synthetic Lethality, a concept in which the combination of two non-lethal genetic or molecular events results in cell death or impairment. When either of these events occurs alone, it is not lethal, but when they happen coupled, they create a lethal condition for the cell. In this work we report that statins emerged from a computational data analysis that we performed on approximately 37,000 synthetic lethality couples. We performed this analysis to select repurposable drugs that could target genes involved in Synthetic Lethality couples with metastatic genes. We validated our discoveryin vitroby drug tests performed on cell lines derived from cancers of the breast, ovary, and cervix. Our data-driven drug repurposing strategy allowed us to understand the molecular basis of the anticancer effect of statins, a discovery which can be directly translated into practical clinical applications in oncology.

show abstract

CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy

Cited by 20 publications

References 221 publications

Contemporary Approaches to Immunotherapy of Solid Tumors

Contemporary Approaches to Immunotherapy of Solid Tumors

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma

The molecular basis of the anticancer effect of statins

Contact Info

Product

Resources

About